Topic: autoimmune disease
The funding will carry Cyteir's RAD51 inhibitors into the clinic for cancer.
AstraZeneca has carved off six inflammation and autoimmune assets to create a new biotech, Viela Bio.
Aldeyra Therapeutics and Janssen inked a pact to develop new drugs for inflammatory diseases.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.
The asset is a recombinant protein designed by AB Biosciences to improve on existing intravenous immunoglobulin therapies.
French scientists discovered that an X chromosome-linked abundance of a toll-like receptor could be the root cause of lupus.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
Pfizer has set up a new partnering network to try to foster collaborations with top-tier universities
Just over a year ago Syntimmune announced Boehringer and Pfizer veteran David de Graaf, Ph.D., as its new CEO. Now he’s out the door.
The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.